Skip to main content
. 2019 Nov 26;2019:8295054. doi: 10.1155/2019/8295054

Figure 1.

Figure 1

Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.